Return to content in this issue


Ebastine in the treatment of allergic rhinitis and urticaria: 30 years of clinical studies and real-world experience

Sastre J

Department of Allergy, Fundación Jimenez Diaz, Madrid. CIBERES, Instituto Carlos III. Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain

J Investig Allergol Clin Immunol 2020; Vol. 30(3)
doi: 10.18176/jiaci.0401

Histamine, acting predominantly via the H1-receptor, is an important mediator of the symptoms of allergy, and H1-antihistamines, which stabilise the receptor in its inactive form, are the treatment of choice for some chronic allergic conditions. Ebastine is a well-established oral second-generation H1-antihistamine. It is administered once daily at a dose of 10–20 mg and is available as a standard tablet and also as a fast-dissolving tablet that disintegrates in the mouth. Ebastine has demonstrated to be efficacious at relieving symptoms in patients with allergic rhinitis or urticaria in multiple clinical trials. Ebastine has modulating effects on the allergic inflammatory process in addition to its antihistamine effects, which may help explain the beneficial effect it has on nasal obstruction in some patients. Ebastine is generally well tolerated at recommended doses and is one of the lowest-risk antihistamines with respect to adverse cognitive/psychomotor effects, confirmed after decades of pharmacovigilance. New long-term data confirm its efficacy and tolerability during up to 1 year of treatment in patients with chronic urticaria.

Key words: Allergic rhinitis, Urticaria, Ebastine, Antihistamines, H1-receptor antagonists